Prime Medicine settles arbitration with Myeloid for $13.5M payment

Prime Medicine, Inc.

Company to pay Myeloid $13.5M to resolve two arbitration proceedings related to former research collaboration.
Settlement includes mutual covenants and release of all claims between parties.
Arbitrations previously disclosed in Q3 2023 Form 10-Q.
Agreement dated January 4, 2024, entered into between Prime Medicine and Myeloid.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.